Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics Versus Standard of Care Antibiotics and Diagnostics in Patients With Bloodstream Infection, Hospital-acquired Pneumonia or Ventilator-associated Pneumonia Due to Pseudomonas Aeruginosa or Carbapenemase Producing Enterobacterales (RAPID)

NCT05979545 is registered in ClinicalTrials.gov with National University of Singapore as lead sponsor.

NCT NCT05979545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05979545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics Versus Standard of Care Antibiotics and Diagnostics in Patients With Bloodstream Infection, Hospital-acquired Pneumonia or Ventilator-associated Pneumonia Due to Pseudomonas Aeruginosa or Carbapenemase Producing Enterobacterales (RAPID)
Lead sponsor
National University of Singapore
Phase
Phase 4
Overall status
Recruiting
Start date
December 12, 2023
Completion date
December 31, 2026
Enrollment
1,900 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

blood stream infections, carbapenem-resistant enterobacteriaceae infection, healthcare associated infection, hospital-acquired pneumonia, ventilator associated pneumonia